NCT00843011View on ClinicalTrials.gov

Food and Relative Bioavailability Study

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

August 28, 2008

Primary Completion Date

October 23, 2008

Study Completion Date

October 23, 2008

Conditions
Depressive Disorder
Interventions
DRUG

Orvepitant

Orvepitant 60 mg, single dose. 2 different formulation. Formulation 2 is administered with and without food.

Trial Locations (1)

37134

GSK Investigational Site, Verona

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00843011 - Food and Relative Bioavailability Study | Biotech Hunter | Biotech Hunter